Research in haemophilia B - approaching the request for high evidence levels in a rare disease

Haemophilia

Volumn 21, Issue 1, 2015, Pages 4-20

  Berger, K ^a   Schopohl, D ^a   Hilger, A ^b   Behr Gross, M E ^c   Giangrande, P ^d   Peyvandi, F ^e   Seitz, R ^b   Schramm, W ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c European Network of National Information Centers   (France)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Evidence level; Factor IX concentrate; Haemophilia B; Literature research; Rare disease; Registered trials

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ALLERGIC REACTION; BIBLIOGRAPHIC DATABASE; COMPARATIVE STUDY; DEVELOPED COUNTRY; GENE THERAPY; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RARE DISEASE; REVIEW; SCREENING TEST; STUDY DESIGN;

HEMOPHILIA B; HUMANS; QUALITY OF LIFE; RARE DISEASES;

EID: 84921600779     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12603     Document Type: Review

References (48)

1. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011; 106: 398-404.
2. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
3. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
4. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
5. Mannucci PM, Franchini M. Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Transfus 2013; 11(Suppl 4): s77-81.
6. Kaiser J. Clinical research. Gene therapists celebrate a decade of progress. Science 2011; 334: 29-30.
7. European Medicines Agency: Central authorisation of medicines. Available at http://www.ema.europa.eu/ema/indexjsp?curl=-pages/about_us/general/general_content_000109jsp&mid=WC0b01ac0580028a47. Accessed March 26, 2013.
8. World Health Organization: Compilation of Terms and Definitions; 10. Developed/developing countries (Intergovernmental negotiating body INB secreteriat note); 13 November 2001. Available at http://apps.who.int/gb/fctc/PDF/inb3/einb3id1.pdf. Accessed July 31, 2014.
9. Aznar JA, Cabrera N, Matysiak M et al. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Haemophilia 2009; 15: 1243-8.
10. Berntorp E, Keeling D, Makris M et al. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. Haemophilia 2012; 18: 503-9.
11. Lissitchkov T, Matysiak M, Zavilska K et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine((R)), a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
12. Lissitchkov T, Matysiak M, Zawilska K et al. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2010; 16: 240-6.
13. Martinowitz U, Shapiro A, Quon DV et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia 2012; 18: 881-7.
14. Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S et al. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact(R)), results of phase III and IV clinical studies. Haemophilia 2011; 17: 439-45.
15. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-8.
16. Quon DV, Logan L. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Haemophilia 2011; 17: e196-201.
17. Serban M, Skotnicki AB, Colovic M et al. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B. Haemophilia 2012; 18: 175-81.
18. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus 2011; 9: 60-9.
19. Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. Haemophilia 2012; 18: 46-9.
20. Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-9.
21. Stonebraker JS, Bolton-Maggs PH, Brooker M, Farrugia A, Srivastava A. A study of reported factor IX use around the world. Haemophilia 2011; 17: 446-55.
22. Nagel K, Walker I, Decker K, Chan AK, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011; 17: 872-4.
23. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84.
24. Bernardi F, Dolce A, Pinotti M et al. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009; 7: 774-9.
25. Chavali S, Ghosh S, Bharadwaj D. Hemophilia B is a quasi-quantitative condition with certain mutations showing phenotypic plasticity. Genomics 2009; 94: 433-7.
26. Hamasaki-Katagiri N, Salari R, Simhadri VL et al. Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia 2012; 18: 933-40.
27. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-31.
28. Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18: e91-4.
29. Nathwani AC, Tuddenham EG, Rangarajan S et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65.
30. Tuddenham E. Gene therapy for haemophilia B. Haemophilia 2012; 18(Suppl 4): 13-17.
31. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012; 18: 268-75.
32. Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41: S360-8.
33. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012; 18: e140-53.
34. Taki M, Shirahata A. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Haemophilia 2009; 15: 78-82.
35. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
36. Aznar JA, Lucia F, Abad-Franch L et al. Haemophilia in spain. Haemophilia 2009; 15: 665-75.
37. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
38. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res 2013; 131(Suppl 2): S11-14.
39. Santagostino E. PROLONG-9FP clinical development program-phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2013; 131(Suppl 2): S7-10.
40. Lissitchkov T, Matysiak M, Zavilska K et al. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine(R)) and a recombinant factor IX (BeneFIX(R)) in patients with severe haemophilia B. Haemophilia 2013; 19: 674-8.
41. Solano Trujillo MH, Stasyshyn O, Rusen L et al. Safe switching from a pdFIX (Immunine) to a rFIX (Bax326). Haemophilia 2014; 20: 674-81.
42. Windyga J, Lissitchkov T, Stasyshyn O et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level
43. Windyga J, Lin VW, Epstein JD et al. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study. Haemophilia 2014; 20: 362-8.
44. Windyga J, Lissitchkov T, Stasyshyn O et al. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study. Haemophilia 2014; 20: 651-58.
45. Shafer F, Smith L, Vendetti N, Rendo P, Carr M. Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia 2014; 20: 349-53.
46. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20: 398-406.
47. Berntorp E, Astermark J, Baghaei F et al. Report no. 208E of the Swedish Council on Health Technology Assessment (SBU): Treatment of Hemophilia A and B and von Willebrand Disease; ISBN: 978-91-85413-44-7. 2011.
48. Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Joint WFH-ISTH session: issues in clinical trial design. Haemophilia 2014; 20(Suppl 4): 137-44.